7 min read
|
Saved February 14, 2026
|
Copied!
Do you care about this?
Louis Andre, backed by investors like Sam Altman and Masayoshi Son, is launching Episteme to create a modern-day research hub similar to Bell Labs. The initiative seeks to free scientists from grant-writing and bureaucratic pressures, allowing them to focus on groundbreaking research across various fields. The goal is to foster innovation and produce commercially viable products.
If you do, here's more
Louis Andre, a 27-year-old scientist with a background in neuroscience and computer science, is launching a new venture called Episteme, backed by notable investors like Sam Altman and Masayoshi Son. Based in San Francisco, Episteme aims to create a modern equivalent of Bell Labs, attracting top scientists to work on diverse, impactful research without the typical pressures of grant writing and fundraising. Andre envisions a space where researchers can focus on meaningful ideas and have access to resources and support for commercialization.
The initiative arose from discussions between Andre and Altman about the frustrations faced by academics, who often spend more time on paperwork than on research. They plan to pay researchers well and offer them equity in the company, allowing them to prioritize innovation. The goal is to recruit around 2,400 scientists, starting with a core group of 15 from various fields like energy and neuroscience. Advisors like Priyamvada Natarajan highlight the broad range of disciplines Episteme will cover, including AI and new materials.
While ambitious, Episteme faces challenges typical of investor-backed research organizations, such as funders losing interest or demanding quick results. Andre and Altman acknowledge the need for regular assessments of projects but emphasize a commitment to giving researchers the freedom and time to develop their work properly. The exact funding details remain undisclosed, but the venture seeks to balance commercial viability with a genuine focus on long-term scientific exploration.
Questions about this article
No questions yet.